Literature DB >> 16153261

Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections.

J-E Berdal1, I Skråmm, P Mowinckel, P Gulbrandsen, J V Bjørnholt.   

Abstract

Prosthetic joint infections are difficult to eradicate, and antibiotic and surgical treatment strategies lack standardisation. The present study followed 29 patients (median age 72 years, median American Society of Anesthesia score of two) with early prosthetic joint infections. Treatment consisted of device retention, surgical debridement and therapy with rifampicin and ciprofloxacin for 3 months. This treatment regimen failed in five patients during the study, with a median observation period of 674 days. The results of this study confirm the findings of the only previous study on device retention with antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153261     DOI: 10.1111/j.1469-0691.2005.01230.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  27 in total

Review 1.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 2.  Treatment of acute periprosthetic infections with prosthesis retention: Review of current concepts.

Authors:  Jesse Wp Kuiper; Robin Tjeenk Willink; Dirk Jan F Moojen; Michel Pj van den Bekerom; Sascha Colen
Journal:  World J Orthop       Date:  2014-11-18

3.  Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA.

Authors:  Carlos J Sanchez; Stefanie M Shiels; David J Tennent; Sharanda K Hardy; Clinton K Murray; Joseph C Wenke
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

4.  Aggressive early débridement for treatment of acutely infected cemented total hip arthroplasty.

Authors:  Mohamed Sukeik; Shelain Patel; Fares Sami Haddad
Journal:  Clin Orthop Relat Res       Date:  2012-11       Impact factor: 4.176

5.  Predictors of treatment outcome in prosthetic joint infections treated with prosthesis retention.

Authors:  Ari-Pekka Puhto; Teija Puhto; Tuukka Niinimäki; Pasi Ohtonen; Juhana Leppilahti; Hannu Syrjälä
Journal:  Int Orthop       Date:  2015-07-03       Impact factor: 3.075

6.  In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid.

Authors:  B Hellmark; M Unemo; A Nilsdotter-Augustinsson; B Söderquist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-12       Impact factor: 3.267

Review 7.  Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

8.  Current management of prosthetic joint infections in adults: results of an Emerging Infections Network survey.

Authors:  Jonas Marschall; Michael A Lane; Susan E Beekmann; Philip M Polgreen; Hilary M Babcock
Journal:  Int J Antimicrob Agents       Date:  2013-01-09       Impact factor: 5.283

9.  Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study.

Authors:  Y Achermann; K Eigenmann; B Ledergerber; L Derksen; P Rafeiner; M Clauss; R Nüesch; C Zellweger; M Vogt; W Zimmerli
Journal:  Infection       Date:  2012-09-19       Impact factor: 3.553

Review 10.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.